Although troponins, the calcium-regulatory protein for the calcium regulation of contractile function found in both skeletal and cardiovascular muscle, there are also isoforms of troponins which are expressed specifically in the heart. One of the best indicative tests; cardiac troponin (cTn) assays has been created by using these cardiac-restricted epitopes within these proteins. For the past decade, cTn has been viewed as the best markerfor acute myocardial necrosis: the indicator of acute myocardial infarction (AMI). Myocardial infarction (MI) is supposedly the presence of myocardial necrosis along with myocardial ischemia. The early recognition of MI is necessary for administrating anti-thrombotic therapy to minimize myocardial damage and preserve cardiac function. Elevated troponin levels in the absence of acute coronary syndrome should incite an assessment for alternative, non-thrombotic mechanism of troponin increment and direct management at the underlying cause. This review describes the clinical utilization of troponinas a biomarker for AMI suspected patients.
HTML PDFShare this article
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report
